Resources
Where to read the methods and the evidence.
Everything Dōsys publishes about how its calculators work is on the product sites and linked here, without a form.
Vancomyzer methods
Published on vancomyzer.com.
- Equations and derivations
Every equation and constant the calculator uses, with the reference check for a typical adult.
- Literature reproducibility
Published vancomycin cases run through the calculator, pass/fail.
- Predictive performance
A developer-run synthetic analysis; not real patients.
- Comparison with Tucuxi
The same prior and simulated levels given to a separately built program.
- Frequently asked questions
Why the Colin 2019 model, how serum creatinine and body weight are handled, and what has been validated.
Evidence status
One page for both products.
What has been checked, by whom, and what has not: Methods and evidence status. Vancomyzer has not been validated in real patients; Dōsys Parenteral Nutrition is an evaluation release for synthetic cases only.
Literature
The papers cited across this site.
Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: a revised consensus guideline. Am J Health-Syst Pharm. 2020;77(11):835–864.
doi:10.1093/ajhp/zxaa036Source of the AUC₂₄ 400–600 mg·h/L target; recommends AUC-guided monitoring, preferably with Bayesian estimation.
Colin PJ, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis. Clin Pharmacokinet. 2019;58(6):767–780.
doi:10.1007/s40262-018-0727-5The population model used in Vancomyzer.
Abdelmessih E, et al. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis. Pharmacotherapy. 2022;42(9):741–753.
doi:10.1002/phar.272210 studies, 4,231 patients; OR 0.625 (95% CI 0.469–0.834) for AKI with AUC-guided dosing. The authors grade the evidence low and note possible confounding.
Lodise TP, et al. Relationship between vancomycin trough concentrations and nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330–1336.
doi:10.1128/AAC.01602-07Nephrotoxicity rose with trough concentrations ≥ 15 mg/L in this cohort.
Hall NM, et al. Model-informed precision dosing improves outcomes in patients receiving vancomycin for gram-positive infections. Open Forum Infect Dis. 2024;11(1):ofae002.
doi:10.1093/ofid/ofae002Single-center retrospective cohort, n = 300, using a different Bayesian product. Not evidence about Vancomyzer.
For hospitals
Evaluations, not pilots.
A hospital interested in evaluating Vancomyzer starts with a feasibility discussion. Protocol, endpoints, approvals and data handling are agreed before any study begins; a contact request does not enroll a hospital or authorize clinical use.